Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California ephedra

This article was originally published in The Tan Sheet

Executive Summary

Latest state legislative action concerning ephedrine alkaloid-containing supplements would limit their sale to "behind-the-counter" status and require labeling warn consumers that exceeding the recommended dose may lead to "heart attack and stroke." SB 397, introduced March 12 by Assemblywoman Jackie Speier, a San Francisco-area Democrat, is similar to legislation introduced by Susan Davis last session. That measure was vetoed by Gov. Gray Davis Sept. 30. Susan Davis currently represents California's 49th district in the U.S. House; her former health staffer now works for Speier. SB 397 was read once and sent to the Committee on Health & Human Services. A hearing is scheduled for April 4
Advertisement

Related Content

Sport Supplement High School Education Program Urged In California Bill
Sport Supplement High School Education Program Urged In California Bill
Sport Supplement High School Education Program Urged In California Bill
Ephedra, Andro, Creatine Easy Access, Lack Of Safety Data Cited By CR
Ephedra, Andro, Creatine Easy Access, Lack Of Safety Data Cited By CR
Ephedra, Andro, Creatine Easy Access, Lack Of Safety Data Cited By CR
Ephedra, Meth Precursors Focus Of State Legislation
Ephedra, Meth Precursors Focus Of State Legislation
Ephedra, Meth Precursors Focus Of State Legislation

Topics

Advertisement
UsernamePublicRestriction

Register

PS092328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel